Glyco-engineered Mammalian Cell Expression System

Glyco-engineered Mammalian Cell Expression System

With many years of experience in glycoengineering, CD BioGlyco has solved various shortcomings of the expression systems and brought customers high-quality cell lines to produce glycoproteins. We have confidence to be your essential research assistant in the field of glycobiology.


New biotherapeutic glycoproteins, such as recombinant monoclonal antibodies (mAb), have been widely used to treat many diseases. Numerous studies have shown that proper glycosylation can improve protein properties, such as increasing stability, extending half-life and reducing immunogenicity. It has been proved that the N-glycan attached to the constant region of an antibody is crucial for the biological efficacy of the antibody, and the minor modification of the N-glycan structure can also dictate the potency of the IgG effector function, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cells toxicity (ADCC). At present, the number of therapeutic glycoproteins produced on mammalian expression platforms continues to increase. This trend is induced by the increased recognition of the importance of post-translational modification (PTM). The development of genetic modification strategies for mammalian cells not only increases the specific production rate, but also optimizes its glycoform distribution to increase its therapeutic activity.

Fig 1. (A) Illustrations of representative N-glycans from human cells/tissues and characteristic structures from (B) CHO cells, (C) mouse myeloma cells, (D) P. pastoris, (E) insect cells and (F) plantsFig 1. (A) Illustrations of representative N-glycans from human cells/tissues and characteristic structures from (B) CHO cells, (C) mouse myeloma cells, (D) P. pastoris, (E) insect cells and (F) plants (Dicker, M.; Strasser, R. 2015)


The Glyco-engineered mammalian cell expression systems in CD BioGlyco include but are not limited to the following.

  • Human cell line

One way to produce human-like glycosylation is to use human cell lines to produce recombinant glycoproteins. Although not optimal, glycoprotein generated using such method will not cause an immune response. We provide the most commonly used human cell lines: HEK293 cells and HT-1080 cells. HEK293 cells are mainly used for transient protein expression and adenovirus production.

  • Chinese hamster ovary cells (CHO)

Among the expression systems of mammalian cells, CHO cells are by far the most commonly used cell line. The cell line has a high protein production rate, is suitable for large-scale industrial suspension culture, and can be adapted to various serum-free and chemically defined medium. The sugar chain of the protein is consistent with that of humans, and the resulting products are more likely to be compatible and biologically active in human host cells. In addition, these cells are not interfered by human viruses, thereby minimizing the biosafety risks of commercial production.

  • Baby hamster kidney cells (BHK)

BHKs are mainly used to produce vaccines. Currently, only two recombinant glycoproteins are produced using BHK cells, coagulation factors VIIa and VIII. These macromolecular proteins are very challenging for BHK cells due to their massive glycosylation and sulfation.


  • Biopharmaceutical research
  • Improve the biological activity of recombinant proteins
  • Genetic engineering drug production
  • Discovery of new genes
  • Glycoprotein structure and function research

Advantages of Us

  • Efficient expression vector, optimized protein expression strategies
  • Reliable and stable manufacturing process
  • Minimal batch-to-batch variation
  • High productivity of sugar-related products
  • One-stop service, 24 hours after-sales service

CD BioGlyco provides a variety of mammalian cell lines for the production of glycoproteins. The optimized expression vectors and expression strategies can greatly increase the expression yield under the premise of ensuring product stability.

Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.


  1. Dicker, M.; Strasser, R. Using glycoengineering to produce therapeutic proteins. Expert Opinion on Biological Therapy. 2015, 15(10): 1501-1516.
  2. Popp, O.; et al. Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function. mAbs. 2017, 10(2): 290-303.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.